Journal
TARGETED ONCOLOGY
Volume 9, Issue 3, Pages 183-193Publisher
SPRINGER
DOI: 10.1007/s11523-013-0303-8
Keywords
Renal cell carcinoma; Pazopanib; Axitinib; Everolimus; Temsirolimus; Tyrosine kinase inhibitors; Mammalian target of rapamycin inhibitors
Categories
Ask authors/readers for more resources
Prior to 2005, the treatment options for metastatic renal cell carcinoma (mRCC) were limited. There has been a proliferation of agents since the introduction of sorafenib, sunitinib, and becavicumab for clinical use in advanced renal cell carcinoma. Recently, four new agents have been approved by the US Food and Drug Administration (FDA) for use in mRCC. These agents come from two unique targeted pathways for RCC, tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors. This review examines the investigational evolution, phases of development, adverse event profiles, and future directions of pazopanib, axitinib, everolimus, and temsirolimus as well as new novel agents being explored in clinical trials for these targeted pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available